In contrast, DUSP22 deletion enhances HCC827 cell sensitivity to gefitinib, suggesting that DUSP22 loss promotes EGFR dependence in lung cancer, and targeting EGFR could be a more effective therapeutic approach for DUSP22-deficient lung tumors. Here, DUSP22 is linked to lung carcinoma.